Rilonacept
Rilonacept
Rilonacept (pronounced: ril-oh-nuh-sept) is a dimeric fusion protein used in the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS). It is also known by its brand name, Arcalyst.
Etymology
The name "Rilonacept" is derived from the combination of the words "Rilon" and "cept". "Rilon" is a prefix used in pharmacology to denote drugs that are receptor antagonists, while "cept" is a suffix used to denote drugs that are receptor inhibitors.
Usage
Rilonacept is used to treat Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). It works by blocking the action of a certain protein in the body that causes inflammation.
Related Terms
- Cryopyrin-Associated Periodic Syndromes (CAPS)
- Familial Cold Autoinflammatory Syndrome (FCAS)
- Muckle-Wells Syndrome (MWS)
- Inflammation
- Protein
Side Effects
Common side effects of Rilonacept include injection site reactions, upper respiratory tract infections, and headache. Serious side effects may include serious infections and allergic reactions.
Precautions
Before using Rilonacept, patients should inform their healthcare provider if they have any history of tuberculosis, if they are scheduled for any vaccines, or if they are pregnant, planning to become pregnant, or breastfeeding.
External links
- Medical encyclopedia article on Rilonacept
- Wikipedia's article - Rilonacept
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski